Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018 (2018), Article ID 4720532, 14 pages
https://doi.org/10.1155/2018/4720532
Research Article

Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer’s Disease: In Vitro and In Vivo Evidence

1Department of Physiology and Pharmacology “V. Erspamer”, Sapienza University of Rome, Rome, Italy
2Department of Psychiatry, University of Naples SUN, Naples, Italy
3Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy

Correspondence should be addressed to Tommaso Cassano

Received 25 May 2017; Revised 2 October 2017; Accepted 23 October 2017; Published 16 January 2018

Academic Editor: Bruno Meloni

Copyright © 2018 Maria Rosanna Bronzuoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Anand, K. D. Gill, and A. A. Mahdi, “Therapeutics of Alzheimer’s disease: past, present and future,” Neuropharmacology, vol. 76, pp. 27–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Braak and E. Braak, “Neuropil threads occur in dendrites of tangle—bearing nerve cells,” Neuropathology and Applied Neurobiology, vol. 14, no. 1, pp. 39–44, 1988. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Merz, H. Wisniewski, R. Somerville, S. A. Bobin, C. L. Masters, and K. Iqbal, “Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques,” Acta Neuropathology, vol. 60, no. 1-2, pp. 113–124, 1983. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Rodríguez, M. Olabarria, A. Chvatal, and A. Verkhratsky, “Astroglia in dementia and Alzheimer’s disease,” Cell Death & Differentiation, vol. 16, no. 3, pp. 378–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, and G. M. Cole, “Inflammation and Alzheimer’s disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Verkhratsky, M. Olabarria, H. N. Noristani, C. Y. Yeh, and J. J. Rodriguez, “Astrocytes in Alzheimer’s disease,” Neurotherapeutics, vol. 7, no. 4, pp. 399–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Verkhratsky, M. V. Sofroniew, A. Messing et al., “Neurological diseases as primary gliopathies: a reassessment of neurocentrism,” ASN Neuro, vol. 4, no. 3, article AN20120010, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Yang and K. K. W. Wang, “Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker,” Trends in Neurosciences, vol. 38, no. 6, pp. 364–374, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Esposito, C. Scuderi, J. Lu, C. Savani, D. De Filippis, and T. Iuvone, “S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells,” Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 914–927, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. L. J. van Eldik and M. S. Wainwright, “The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain,” Restorative Neurology and Neuroscience, vol. 21, no. 3-4, pp. 97–108, 2003. View at Google Scholar
  11. C. Lindberg, E. Hjorth, C. Post, B. Winblad, and M. Schultzberg, “Cytokine production by a human microglial cell line: effects of ßamyloid and α-melanocyte-stimulating hormone,” Neurotoxicity Research, vol. 8, no. 3-4, pp. 267–276, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. G. C. Brown and A. Bal-Price, “Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria,” Molecular Neurobiology, vol. 27, no. 3, pp. 325–355, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. E. Burda and M. V. Sofroniew, “Reactive gliosis and the multicellular response to CNS damage and disease,” Neuron, vol. 81, no. 2, pp. 229–248, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Steardo Jr., M. R. Bronzuoli, A. Iacomino, G. Esposito, L. Steardo, and C. Scuderi, “Does neuroinflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes,” Frontiers in Neuroscience, vol. 9, p. 259, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Scuderi, C. Stecca, M. Valenza et al., “Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease,” Cell Death & Disease, vol. 5, no. 9, article e1419, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. E. O'Bryant, V. Hobson, J. R. Hall et al., “Brain-derived neurotrophic factor levels in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 17, no. 2, pp. 337–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. N. Voineskos, J. P. Lerch, D. Felsky, S. Shaikh, T. K. Rajji, and D. Miranda, “The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease,” Archives of General Psychiatry, vol. 68, no. 2, pp. 198–206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. V. K. Sandhya, R. Raju, R. Verma et al., “A network map of BDNF/TRKB and BDNF/p75NTR signaling system,” Journal of Cell Communication and Signaling, vol. 7, no. 4, pp. 301–307, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Scuderi, G. Esposito, A. Blasio, M. Valenza, P. Arietti, and L. Steardo Jr., “Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide,” Journal of Cellular and Molecular Medicine, vol. 15, no. 12, pp. 2664–2674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Scuderi, M. Valenza, C. Stecca, G. Esposito, M. R. Carratù, and L. Steardo, “Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α,” Journal of Neuroinflammation, vol. 9, no. 1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. G. D'Agostino, R. Russo, C. Avagliano, C. Cristiano, R. Meli, and A. Calignano, “Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease,” Neuropsychopharmacology, vol. 37, no. 7, pp. 1784–1792, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Tomasini, A. C. Borelli, S. Beggiato, L. Ferraro, T. Cassano, and S. Tanganelli, “Differential effects of palmitoylethanolamide against amyloid-β induced toxicity in cortical neuronal and astrocytic primary cultures from wild-type and 3xTg-AD mice,” Journal of Alzheimer’s Disease, vol. 46, no. 2, pp. 407–421, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Petrosino and V. Di Marzo, “The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations,” British Journal of Pharmacology, vol. 174, no. 11, pp. 1349–1365, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Costa, S. Conti, G. Giagnoni, and M. Colleoni, “Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems,” British Journal of Pharmacology, vol. 137, no. 4, pp. 413–420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. S. L. Grillo, J. Keereetaweep, M. A. Grillo, K. D. Chapman, and P. Koulen, “N-Palmitoylethanolamine depot injection increased its tissue levels and those of other acylethanolamide lipids,” Drug Design, Development and Therapy, vol. 7, pp. 747–752, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Scuderi, C. Stecca, M. R. Bronzuoli et al., “Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer’s disease,” Frontiers in Pharmacology, vol. 5, p. 89, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Baudier, C. Delphin, D. Grunwald, S. Khochbin, and J. J. Lawrence, “Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 23, pp. 11627–11631, 1992. View at Publisher · View at Google Scholar
  29. C. Scotto, J. C. Deloulme, D. Rousseau, E. Chambaz, and J. Baudier, “Calcium and S100B regulation of p53-dependent cell growth arrest and apoptosis,” Molecular and Cellular Biology, vol. 18, no. 7, pp. 4272–4281, 1998. View at Publisher · View at Google Scholar
  30. Y. Sato, Y. Chin, T. Kato et al., “White matter activated glial cells produce BDNF in a stroke model of monkeys,” Neuroscience Research, vol. 65, no. 1, pp. 71–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Parpura, M. T. Heneka, V. Montana et al., “Glial cells in (patho)physiology,” Journal of Neurochemistry, vol. 121, no. 1, pp. 4–27, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Verkhratsky, R. Zorec, J. J. Rodríguez, and V. Parpura, “Astroglia dynamics in ageing and Alzheimer’s disease,” Current Opinion in Pharmacology, vol. 26, pp. 74–79, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Pekny and M. Pekna, “Reactive gliosis in the pathogenesis of CNS diseases,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1862, no. 3, pp. 483–491, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. Liddelow, K. A. Guttenplan, L. E. Clarke et al., “Neurotoxic reactive astrocytes are induced by activated microglia,” Nature, vol. 541, no. 7638, pp. 481–487, 2017. View at Publisher · View at Google Scholar
  35. M. Olabarria, H. N. Noristani, A. Verkhratsky, and J. J. Rodriguez, “Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease,” Glia, vol. 58, no. 7, pp. 831–838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. V. C. Jones, R. Atkinson-Dell, A. Verkhratsky, and L. Mohamet, “Aberrant iPSC-derived human astrocytes in Alzheimer’s disease,” Cell Death & Disease, vol. 8, no. 3, article e2696, 2017. View at Publisher · View at Google Scholar
  37. A. Verkhratsky, V. Parpura, M. Pekna, M. Pekny, and M. Sofroniew, “Glia in the pathogenesis of neurodegenerative diseases,” Biochemical Society Transactions, vol. 42, no. 5, pp. 1291–1301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. P. C. Chen, M. R. Vargas, A. K. Pani et al., “Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2933–2938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Bradford, J. Y. Shin, M. Roberts et al., “Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice,” Journal of Biological Chemistry, vol. 285, no. 14, pp. 10653–10661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Acosta, H. D. Anderson, and C. M. Anderson, “Astrocyte dysfunction in Alzheimer disease,” Journal of Neuroscience Research, vol. 95, no. 12, pp. 2430–2447, 2017. View at Publisher · View at Google Scholar
  41. M. R. Bronzuoli, A. Iacomino, L. Steardo, and C. Scuderi, “Targeting neuroinflammation in Alzheimer’s disease,” Journal of Inflammation Research, vol. 9, pp. 199–208, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Basso, J. Yang, L. Warren et al., “Volumetry of amygdala and hippocampus and memory performance in Alzheimer’s disease,” Psychiatry Research: Neuroimaging, vol. 146, no. 3, pp. 251–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. D. P. Devanand, G. Pradhaban, X. Liu et al., “Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease,” Neurology, vol. 68, no. 11, pp. 828–836, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Pennanen, M. Kivipelto, S. Tuomainen et al., “Hippocampus and entorhinal cortex in mild cognitive impairment and early AD,” Neurobiology of Aging, vol. 25, no. 3, pp. 303–310, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Wolf, A. Hensel, F. Kruggel et al., “Structural correlates of mild cognitive impairment,” Neurobiology of Aging, vol. 25, no. 7, pp. 913–924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. R. I. Scahill, J. M. Schott, J. M. Stevens, M. N. Rossor, and N. C. Fox, “Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 7, pp. 4703–4707, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. M. V. Sofroniew and H. V. Vinters, “Astrocytes: biology and pathology,” Acta Neuropathologica, vol. 119, no. 1, pp. 7–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Bhattacharyya, R. W. Oppenheim, D. Prevette, B. W. Moore, R. Brackenbury, and N. Ratner, “S100 is present in developing chicken neurons, and Schwann cells, and promotes neuron survival in vivo,” Journal of Neurobiology, vol. 23, no. 4, pp. 451–466, 1992. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Zetterberg, D. H. Smith, and K. Blennow, “Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood,” Nature Reviews Neurology, vol. 9, no. 4, pp. 201–210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Minghetti, “Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 9, pp. 901–910, 2004. View at Publisher · View at Google Scholar
  51. M. A. Meraz-Ríos, D. Toral-Rios, D. Franco-Bocanegra, J. Villeda-Hernández, and V. Campos-Peña, “Inflammatory process in Alzheimer’s disease,” Frontiers in Integrative Neuroscience, vol. 7, p. 59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Esposito, D. Impellizzeri, E. Mazzon, I. Paterniti, and S. Cuzzocrea, “Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson’s disease,” PLoS One, vol. 7, no. 8, article e41880, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Rahimi, M. Faizi, F. Talebi, F. Noorbakhsh, F. Kahrizi, and N. Naderi, “Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice,” Neuroscience, vol. 290, pp. 279–287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. S. D. Skaper, A. Buriani, R. Dal Toso et al., “The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 9, pp. 3984–3989, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. D. M. Lambert, S. Vandevoorde, G. Diependaele, S. J. Govaerts, and A. R. Robert, “Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice,” Epilepsia, vol. 42, no. 3, pp. 321–327, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Impellizzeri, G. Bruschetta, M. Cordaro et al., “Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain,” Journal of Neuroinflammation, vol. 11, no. 1, p. 136, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. K. R. Stover, M. A. Campbell, C. M. Van Winssen, and R. E. Brown, “Analysis of motor function in 6-month-old male and female 3xTg-AD mice,” Behavioural Brain Research, vol. 281, pp. 16–23, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Oddo, A. Caccamo, M. Kitazawa, B. P. Tseng, and F. M. LaFerla, “Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease,” Neurobiology of Aging, vol. 24, no. 8, pp. 1063–1070, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. L. M. Billings, S. Oddo, K. N. Green, J. L. McGaugh, and F. M. LaFerla, “Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice,” Neuron, vol. 45, no. 5, pp. 675–688, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. N. A. Castello, K. N. Green, and F. M. LaFerla, “Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter aβ or tau pathology,” PLoS One, vol. 7, no. 8, article e39566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. E. R. Nestmann, “Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential,” Food Science & Nutrition, vol. 5, no. 2, pp. 292–309, 2017. View at Publisher · View at Google Scholar · View at Scopus